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Abstract  
Background: COPD is a common chronic respiratory disease induced by smoking or exposition to 
noxious gases. The most disabling symptom is dyspnea and the first-line treatment to improve 
symptoms are bronchodilators. Usually, bronchodilator response is determined by the improvement of 
forced expiratory volume in one second (FEV₁) which is not well correlated to dyspnea. As the forced 
oscillation technique (FOT) allow to measure parameters related to lung hyperinflation, hallmark of 
severe COPD, which are better correlated with dyspnea, we reasoned that FOT might be an interesting 
tool to assess the bronchodilator response in COPD. 
Aims: To: 
- assess bronchodilator response both with conventional respiratory function tests and FOT, 
with a particular interest for reactance parameters which have been linked to lung 
hyperinflation.  
- assess the correlation between respiratory parameters and intensity of dyspnea 
- determine if changes in reactance parameters after bronchodilator administration are more 
closely related to those of IC than those of FEV₁.  
- determine which changes in respiratory function parameters could predict a clinically 
significant improvement in IC. 
Methods: 26 COPD patients were recruited. They were tested for conventional tests as well as with 
FOT both before and after bronchodilator administration (80 µg of ipratropium bromide and 200 µg of 
fenoterol hydrobromide). 
Analysis: A majority of the parameters responded significantly after bronchodilator administration. A 
reactance parameter came out to be very interesting; the area above the reactance-frequency curve at 
5Hz (AX5) which improved highly significantly after bronchodilator administration (p-value<0,001). 
More importantly, AX5 was correlated with dyspnea (r = 0,41, p-value<0,05) and the changes in AX5 
were better correlated with the changes in IC (r = -0,58, p-value<0,01) than the changes in FEV₁ (r = -
0,47, p-value<0,05). Finally, AX5 was shown to be a good predictor for a clinical and significant 
change in IC, as determined by ROC analysis (AUC=0,80, p-value<0,01).  
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Conclusion: AX5 parameter appears to be an interesting index for the assessment of the bronchodilator 
response. FOT also gives additional information to that of conventional respiratory function tests. 
Accordingly, and because of its ease of use, FOT appears to be an interesting method to assess 
bronchodilator response. 
Keywords: Chronic Obstructive Pulmonary Disease, Forced Oscillation Technique, Bronchodilator 
Response, Reactance, Inspiratory Capacity  
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List of abbreviations 
 
Abbreviation Description 
ATS American thoracic society 
AUC Area under the curve 
AX5 Area above the reactance-frequency curve at 
5Hz 
BD Bronchodilator 
BPM Breaths per minute 
CAT COPD assessment test 
Cm  Centimeter 
cmH2O Centimeter of water 
CO Carbon monoxide 
COPD Chronic Obstructive Pulmonary Disease 
DH Dynamic pulmonary hyperinflation 
DLCO CO transfer capacity 
EELV End-expiratory lung volume 
EFL Expiratory flow limitation 
ERV Expiratory reserve volume 
EVC Expiratory vital capacity 
FEV₁ Forced expiratory volume in one second 
FEV₁/FVC ratio Tiffeneau index 
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FRC Functional residual capacity 
Fres Resonance frequency of the respiratory 
system 
FVC Forced vital capacity 
GOLD Global initiative for chronic obstructive lung 
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KCO CO transfer coefficient 
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mmHg Millimeter of mercury 
MRC Medical research council 
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N/A Not applicable  
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PEEP Positive end-expiratory alveolar pressure 
R Resistance 
R₅ Resistance of the respiratory system at 5Hz 
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R₁₉ Resistance of the respiratory system at 19Hz 
R₁₉,in Inspiratory resistance at 19Hz 
R₁₉,ex Expiratory resistance at 19Hz 
R₅₋₁₉ Difference between resistance of the 
respiratory system at 5 and 19Hz 
R₅₋₁₉,in Difference in inspiratory resistance between 
5 and 19Hz 
R₅₋₁₉,ex Difference in expiratory resistance between 
5 and 19Hz 
RAW Airway resistance 
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RR Respiratory rate  
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s Second  
SD Standard Deviation 
sRAW Specific airway resistance 
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WHO World health organization 
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system at 5Hz 
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1.1. Chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease (COPD) is a very common chronic respiratory disease 
which has a huge impact on the patients’ quality of life. According to the World Health 
Organization (WHO), the prevalence of the disease was 251 million cases of COPD in the world 
in 2016 and more than 3.17 million people died of COPD in 2015, accounting for 5% of all 
deaths worldwide that year. It is also predicted that COPD will become the third cause of death 
in the world by 2020 1 2. 
This disease is due to the inhalation of noxious gases and particles, mostly from tobacco smoke 
or exposure to occupational hazards. It is an incompletely reversible disease characterized by 
progressive airway narrowing and loss of lung elastic recoil resulting in airflow obstruction 
especially if risk factors persist, though the disease requires a certain level-duration of 
exposition to develop 3. In these patients, airway inflammation causes wall thickening by 
hypertrophy of the smooth muscle, as well as reactive hypersecretion of mucus which induce a 
decrease of the diameter of the airway lumen and thus an increased airway resistance (see Figure 
1) 4. According to the Poiseuille equation (R=8.η.L/π.r⁴)1, when the radius decreases by half, 
resistance increases by 16 times 5. 
COPD associated airway obstruction has a reversible part which is related to the contraction of 
airway smooth muscles that could be improved by the use of bronchodilators, inflammation and 
accumulation of mucus in the airway lumen. The irreversible part of airway obstruction is due 
to remodelling, especially fibrosis and narrowing of the diameter of peripheral airways as well 














1 R = Resistance, η = gas viscosity, L = length of the tube, r = radius of the tube 
Figure 1. Illustration of the airway narrowing in COPD patient.           Source: https://s3-ap-southeast-
2.amazonaws.com/assets.asthmafoundation.org.nz/images/_fit640/COPD-diagram_160331_100539.jpg 
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The pathological abnormalities characterizing COPD are on the one hand a disease of the 
airways as discussed above and on the other hand, emphysema. The contribution of these two 
abnormalities varies from patient to patient. Worth of note, emphysema is not always associated 
with airflow obstruction. According to the GOLD guidelines, a patient with chronic bronchitis 
or emphysema cannot be considered as having COPD without the demonstration of airflow 
obstruction at pulmonary function tests 6.  
 
1.1.1. Chronic bronchitis  
Chronic bronchitis is defined on a clinical basis. It is defined by the presence of cough and 
sputum for at least three months per year during two consecutive years 7 8. It is associated with 
an excess of phlegm in the airways due to the hypertrophy of the submucous glands and the 
increased number of goblet cells responsible for cough and sputum. There is also an 
inflammatory infiltrate, a hypertrophy of smooth muscle and an increase in connective tissue. 
All these phenomena induce a reduction of the airway diameter and therefore induces bronchial 
obstruction. And finally have an impact on the resistance properties. It is important to notice 
that chronic bronchitis is not always present in COPD patients. Particularly, cough and sputum 
often disappear after smoking cessation. 
 
1.1.2. Emphysema 
On the other side, emphysema is defined on a pathological basis. It encompasses a destruction 
of the pulmonary alveoli wall with enlargement of the alveolar spaces. This reduces the surface 
for gas exchange and therefore the capacity of oxygen transfer towards the bloodstream 9. 
Emphysema is responsible of a decrease in the pulmonary elastic recoil pressure at a given lung 
volume due to an increase in lung compliance. Rupture of the interalveolar septa is associated 
Figure 2. Illustration of the evolution of changes in lung volumes in case of emphysema.        Source : 
http://www.fondazionecarrel.org/carrel/thorac/files/enphys/new/FIG_3_b.jpg 
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with a widening of the airspaces. This results in an increase in total lung capacity (TLC) and in 
particular in residual volume (RV) thus also an increase in functional residual capacity (FRC) 
(See Figure 2) 10. This increased lung volume is called the lung hyperinflation and this is a 
major determinant of dyspnea in COPD since it is associated with a flattening of the diaphragm 
which puts the latter at mechanical disadvantage.  
The decrease in lung elastic recoil is also an important mechanism for the increase in airway 
resistance. Indeed, the recoil of the lung provides a tethering effect on the airways which tends 
to increase their diameter. Thus, when there is a decrease of this lung elastic recoil, there is a 
reduction of the diameter of the small airways which has also an impact on the reduction in 
expiratory flows 11.  
 
1.2. Dyspnea  
The most disabling symptom of COPD is dyspnea, first induced by physical exercise but 
progressively worsening with disease progression such that it can even be present at rest. By 
definition, dyspnea is the feeling of not getting enough air to breath, also described as “air 
hunger” 12 13. But it is a subjective sensation felt by the patient, so the American Thoracic 
Society (ATS) decided to propose a broader definition of dyspnea for physicians, nurses and 
therapists which is “a term used to characterize a subjective experience of breathing discomfort 
that consists of qualitatively distinct sensations that vary in intensity” 14. The modified Medical 
Research Council (mMRC) proposed a questionnaire which assesses the impact of dyspnea, it 
is the mMRC dyspnea scale that will be used in this study as well as the San Diego Shortness 
of Breath Questionnaire (French version) 15.  
Dyspnea felt by the patient is related to the imbalance between inspiratory muscles capacity 
and the workload these muscles face. To be more precise, it is inversely related to the inspiratory 
muscle capacity and directly related to the requested inspiratory workload. COPD has an impact 
on these two factors as discussed below. 
 
The end expiratory lung volume increases and as a consequence, the inspiratory capacity 
decreases due to different causes. First of all, the increased compliance of the lung (which is 
the inverse of the elastance), due to emphysema, leads to a resetting of the relaxation volume 
of the respiratory system to a higher level than in health, it is the static component of lung 
hyperinflation. 
When airflow obstruction worsens, maximal expiratory flow may be achieved during tidal 
breathing, expiratory flow limitation (EFL) which is a pathophysiologic hallmark of COPD 
appears. This means that even with an increase in pressure drive, there is no increase in flow 
when EFL is present. In others words, there is no more expiratory flow reserve. 
 In patients with EFL during tidal breathing, the end-expiratory lung volume (EELV) is also 
dynamically determined and maintained at a level above the relaxation volume of the 
respiratory system. In flow-limited patients, the time-constant for lung emptying is increased in 
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many alveolar units but the expiratory time is often insufficient to allow EELV to reach to its 
normal relaxation volume, all this inducing air retention (or air trapping) called lung dynamic 
hyperinflation 12. To summarize, EFL promotes dynamic pulmonary hyperinflation (DH) (See 
figure 3). 
EFL has also an impact on the alveolar pressure. Indeed, as EELV is superior than the resting 
volume of the respiratory system when there is DH, the air surplus that stays in the lungs after 
the expiration creates a positive end-expiratory alveolar pressure (PEEP) (See figure 6) which 
needs to be neutralised by the inspiratory muscles before generating a negative alveolar pressure 



















An important factor which decreases the inspiratory muscle capacity is the flattening of the 
diaphragm, the main inspiratory muscle. Indeed, due to lung hyperinflation, COPD patients 
have a flattened diaphragm which loses its dome shape. The vertical portion of the latter, also 
called the zone of apposition is shortened. This portion being the basis for its inspiratory effect, 
the decrease of its effectiveness due to DH is a real disadvantage because the inspiratory effort 
must be higher to inflate the lungs compared to healthy people (See Figure 4) 2. This has a major 
contribution to the genesis of dyspnea  in COPD 12 16.  
Figure 3. Illustration representing the flow-volume curves of an healthy subject (left panel) 
and a COPD patient (right panel). Continuous central lines represent the tidal breathing at 
rest and dotted central lines represent the tidal breathing during exercise. In COPD patient, 
there is a shift on the left to breathe during exercise inducing the patient to breathe at 
higher volume but also a decrease in the inspiratory capacity.       Source :  https://ars.els-
cdn.com/content/image/1-s2.0-S0012369215527566-gr1.jpg 















The rate and magnitude of DH during exercise is generally measured in the laboratory setting 
by serial inspiratory capacity (IC) measurements. Because TLC, which is the volume of gas 
present in the lungs after maximal inspiration, is constant on the short term, a decrease in IC, 
which is the volume of air that can be inspired from EELV up to TLC, is due an increase in 
EELV, also called FRC. See Figure 5. 
 
 
Regarding the inspiratory muscle workload, it has a resistive and an elastic component. The 
resistive one is proportional to the airway resistance (Raw) and the elastic component is 
proportional to the elastance properties. Due to different factors cited above, the airway 
resistance is increased inducing an increase of the resistive component of the inspiratory 
Figure 4.  Illustration of the diaphragm flattening in COPD.     Source : https://encrypted-
tbn0.gstatic.com/images?q=tbn:ANd9GcSX7Wb7UMHwRCCVs_bsTTCZ1xvd_61i3nTdk9PIUy4ZGsxR3ts-rQ 
Figure 5. Illustration of lung volumes and capacitie. Source : 
https://upload.medbullets.com/topic/117009/images/screen%20shot%202012-02-17%20at%208.56.23%20pm.jpg 
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muscles’ workload. The elastic one also increases due to the fact that severe patients breathe at 
higher volume. It is represented on the right image on Figure 6, when a patient breath at higher 
volume, he breath on a flatter portion of the pressure-volume curve where the elastance is 
increase so there is an increase in the elastic component of the inspiratory muscles’ workload. 
Accordingly, the dynamic compliance (measured during tidal breathing) is decreased due to 
DH as opposed to the static lung compliance which is increased due to emphysema. 
 
 
1.3. Evaluation of the respiratory function 
 
1.3.1. Forced vital capacity manoeuvre 
There are different ways to evaluate the respiratory function but the most widely used is 
spirometry, especially the forced vital capacity manoeuvre (See Figure 7). This technique 
provides the following parameters: 
- The forced expiratory volume in one second (FEV₁) which is usually used to assess 
COPD severity as a more pronounced decline is a sign of severity of the disease 
- The forced vital capacity (FVC) 
- With the above parameters, a third one can be calculated; the Tiffeneau index which is 
the FEV₁/FVC ratio. A reduction of this ratio to 70% or less after the administration of 
a bronchodilator is used to define the presence of airflow obstruction, which is included 




Figure 6. Illustration representing the pressure-volume curves of healthy subject (left) and COPD patient 
(right).  Source : https://thorax.bmj.com/content/thoraxjnl/61/4/354/F3.large.jpg 

















1.3.2. Body plethysmography 
Another test used to assess the respiratory function is the body plethysmography. It is a method 
where the patient is sitting in a closed cabin. Compared to spirometry, body plethysmography 
can measure the static lung volumes like residual volume (RV), functional residual capacity 
(FRC), total lung capacity (TLC) and airway resistance (RAW). This technique gives additional 
information regarding lung hyperinflation and airway resistance which are consequences of 
COPD. It has interest because it can give insight in the cause and the severity of dyspnea. 
Indeed, lung hyperinflation is associated with an increased FRC while airway resistance is 
directly related to the resistive work of breathing. As spirometry, body plethysmography 
requires a good collaboration from the patient which may be a limiting factor in their use in the 
case of for example, elderly people. Another issue of these two techniques is that they do not 
assess the reactance of the respiratory system. These disadvantages can be solved using another 
test called the FOT. 
 
1.3.3. Forced oscillation technique 
FOT is a method for non-invasively assessing respiratory mechanics during spontaneous 
breathing (tidal breathing). The FOT is based on the application of a sinusoidal pressure wave 
of specific frequency (from 5 to 37 Hz) within the airways, at the mouth of the patient 18 (See 
figure 8). It measures the impedance of the respiratory system and its two components: 
• the respiratory system resistance which is mainly determined by the airway calibre and 








Figure 7. Tracing of FVC manoeuvre. Abbreviations: FEV₁: forced expiratory volume in one second ; FVC: forced vital 
capacity ; TLC: total lung capacity ; RV: residual volume.     Source: http://bronchiectasis.com.au/wp-
content/uploads/2015/09/Spirometry.png 
Time (s) 
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At low frequencies (typically 5Hz), the inertive component of the reactance is negligible and 
reactance mainly reflects the elastic properties of the respiratory system. Because the ability of 
the lungs to store energy is primarily manifest in the small airways, the reactance at 5Hz (X5) 
can provide information about the small airways. States such as hyperinflation result in more 
negative X5 values 21. The more the lungs are hyperinflated, the more X5 values are negative. 
Recently, it has been shown that the comparative analysis of low frequency reactance measured 
during the inspiratory and expiratory phases of the breathing cycle (∆X5) makes it possible to 
detect the presence of EFL during tidal breathing which is an important determinant of DH and 
dyspnea in case of COPD, as discussed above. Indeed, Dellacà et al determined that a ∆X5 > 
2,8, is an ideal criterion for detecting tidal EFL 22. 
EFL is associated with what is called a choke point in the airways such that the oscillating 
pressure wave generated by the FOT system cannot travel downstream to a chokepoint. This 
results in a considerable decrease in the apparent compliance of the respiratory system. As flow 
limitation usually only occur during expiration, the reactance measured at low frequency during 
expiration is much more impaired than that measured in inspiration when EFL is present during 
tidal breathing. Accordingly, reactance parameters measured by FOT may capture 
physiological changes that are important for the pathogenesis of dyspnea which are not 
necessarily reflected by spirometry parameters or resistance parameters that can also be 
measured by FOT, and thus provide additional information 3. 
Moreover, FOT can give information about the resistance of small airways 21. Indeed, resistance 
measured at 5Hz represents total airway resistance and resistance measured at 19Hz represents 
the resistance of the upper airways. By subtracting R19 from R5 (R5-19), FOT gives 
information about small airways contrary to conventional respiratory function tests which give 
information only total airway resistance that is normally mostly influenced by the upper airways 
21 23. 
In addition to additional informations that it can provide regarding the physiology of the 
respiratory system, the FOT has another big advantage as compared to conventional pulmonary 
function tests: it is easy to use and does not require any particular maneuver to be performed 
by the patient. FOT measurements are indeed acquired during tidal breathing, requiring minimal 




















1.4. Bronchodilator response 
Bronchodilators are used as first-line therapy in COPD with the aim to reduce symptoms, 
particularly improving dyspnea and exercise tolerance. They produce a rapid relaxation of 
airway smooth muscle and thus improve airway calibre and the expiratory flow rate. They lead 
to variable increases in FEV₁.  
The response to bronchodilators can be assessed in a pulmonary functional test laboratory. The 
bronchodilator response is usually measured by the improvement of the FEV₁ (forced expiratory 
volume in one second). However, the correlation between symptoms especially dyspnea and 
FEV₁ is poor 25 26. Indeed, it has been shown that FEV₁ is a suboptimal index for assessing 
bronchodilator response. The performance of spirometry test is affected by the day of testing, 
the severity of baseline lung-function impairment and the number of drugs given to test 17.  
Studies have examined the mechanisms of dyspnea relief after bronchodilatation, showing that 
bronchodilators reduce airway smooth muscle tone, improve airway conductance and enhance 
lung emptying. It accelerates the time constant for lung emptying in alveolar units throughout 
the lungs, thus reducing the dynamically determined end-expiratory lung volume (EELV) in 
patient with expiratory flow limitation. A reduced EELV (resulting in an increased IC) means 
reduced elastic load on and improved functional strength of the inspiratory muscles. All of these 
factors improve dyspnea 12. Studies have shown there is a better correlation between dyspnea 
and inspiratory capacity (IC) than with FEV₁ 26. Dyspnea increases with disease severity as the 
latter is associated with greater DH, and accordingly lower IC.  
Regarding FOT, studies have shown that bronchodilator administration results in decreased 
resistance, especially in the small airways 27. But they also showed that reactance parameters 
were good indicators for a reduction in EFL which is a critical determinant of dyspnea 27. 
Figure 8. Illustration of the superposition of external pressure oscillations sent by the 
Tremoflo® to tidal breathing. Source : tremoFlo C-100 Airwave Oscillometry System 
User Manual  
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Accordingly, we reasoned that it would be useful to use the FOT to assess the changes in 
reactance after bronchodilator administration and their association with the changes in IC and 
FEV₁. We also were interested in the association between reactance indices and dyspnea 
experienced by the patients in their daily life. 
 
2. Specific Aims  
The objectives of the study were first to assess the bronchodilator response of parameters 
measured both by conventional spirometric and by FOT, in particular for the reactance 
parameters as they are related to EFL. These have been relatively forgotten in the literature at 
the expense of resistance parameters studied with both FOT and plethysmography. 
The second objective was to evaluate the correlation between conventional respiratory function 
parameters, FOT parameters and dyspnea intensity assessed using the mMRC and San Diego 
SOBQ questionnaires. 
Given that the correlation between dyspnea and FEV₁ is poor, it is therefore useful in a 
bronchodilator test to study the improvement of IC in addition to that of FEV₁ 25 26. Thus, the 
second objective was to assess if the improvement of the reactance parameter after 
bronchodilator administration is more closely related to that of IC than FEV₁. 
The improvement of IC is not a routine for bronchodilator tests in most of the pulmonary 
functional labs. Moreover, as the forced vital capacity manoeuvre, its measurement requires a 
good patient collaboration. As the FOT is very simple to perform, because it does not need any 
cooperation of the patient, we were very interested in its use for the evaluation of reactance 
parameters and in particular, ∆X5.  
We were also particularly interested to assess whether changes in FOT parameters would 




3.1. Literature review 
A majority of the articles were provided by Mr. Marchand. But the PubMed database was also 
consulted with keywords like “chronic obstructive pulmonary disease (COPD)”, “forced 
oscillation technique”, “reversibility test”, “bronchodilator” and “COPD management”. 
 
3.2. Study sample and recruitment  
Patients were recruited in the patient base of Mr. Marchand respecting the inclusion and 
exclusion criteria in the table below (See table 1). For a question of ease, the measurements 
were made the day of the consultation. 
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Inclusion criteria  Exclusion criteria 
 
- Clinical diagnosis of COPD 
confirmed by post-bronchodilator 
(DUOVENT HFA 4 puffs) 
obstructive airway obstruction 
(FEV1/FVC < Percentile 5) 
persisting after bronchodilatation 
 
- Former or active smoking > 10 
packs/year 
 
- Age > 40 years 
 













- Inability to comply with bronchodilator 
weaning time: 
6 hours for short-acting 
bronchodilators 
12 hours for long-acting 
bronchodilators 
24 hours for very long-acting 
bronchodilators 
 
- Inability to comply with the 4 hours of 
smoking cessation before the 
measurements 
 
- Inability to perform respiratory 
function tests 
 
- Continuous oxygen therapy 
 
- Close angle glaucoma 
 
- History of urinary retention (only for 





- Acute illness contraindicating the 
performance of respiratory tests 
Table 1. Inclusion and exclusion criteria for the participation in this study. 
3.3. Methodology/protocol  
The ethical approval was obtained from the CHU UCL Namur site Godinne Ethics Committee 
on 5th March 2019. The trial was registered on clinicaltrial.gov on 9th April 2019 using the 
clinical trials identifier NCT03910985. 
It was a monocentric study, all the measurements were done at the CHU UCL Namur, site 
Godinne.  
A first contact with the patient was done by phone to explain the protocol of the study and 
answer their questions. Then the informed consent was sent to allow the patient to read it at 
home. 
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During the meeting before the tests, patients’ questions were answered for a good understanding 
of the study. The informed consent was signed by the patient and the investigator (see Annex 
1). 
Then the followings items were obtained preceding the respiratory tests with a questionnaire 
(see Annex 2): anthropometric data (weight and size), personal data (date of birth, age, sex, 
smoking, number of cigarettes/day, pack/years, if former smoker : date of withdrawal and 
number of pack/years), medical data (medical background, thoracic surgical history, current 
medical treatment, the date of diagnosis of COPD and time of the last intake of inhaled 
treatments). 
The assessment of symptoms, recommended by the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD), was evaluated by using CAT questionnaire (CAT = COPD Assessment 
Test) and dyspnea by using mMRC scale (modified Medical Research Council) and the San 
Diego Shortness of Breath Questionnaire (French version). See Annex 3, 4 and 5. 
The assessment of airflow limitation severity was evaluated by the level of FEV₁ after the 
administration of bronchodilator, to see the classification, see the table just below (Table 2) 6. 
Table 2. Classification of airflow limitation severity in COPD (based on post-bronchodilator FEV₁ in patients 
with FEV₁/FVC < 0.70) according to GOLD guidelines. 
Once the patient had answered the different questionnaires, he was weighed and measured. The 
functional respiratory measures were done in this order:  
• FOT,  
• total lung capacity (TLC),  
• airway resistance (Raw),  
• slow vital capacity (slow VC including IC measurement),  
• forced vital capacity (FVC) manoeuvre with measurement of FEV₁ and FEV₁/FVC ratio 
and 
• carbon monoxide (CO) diffusion indices.  
 
Then a short-acting bronchodilator (DUOVENT HFA® 4 puffs) was administrated using an 
inhalation chamber. After 30 minutes of waiting, tests were carried out again in the same order 
except for diffusion indices. 
 
 Air flow limitation severity FEV₁ predicted (%) 
GOLD 1 Mild FEV₁ ≥ 80 
GOLD 2 Moderate 50 ≤ FEV₁ < 80 
GOLD 3 Severe 30 ≤ FEV₁ < 50 
GOLD 4 Very severe  FEV₁ < 30 
Assessing bronchodilator response in COPD using FOT                          
23 
 
a). Forced oscillation technique  
The test started with the TREMOFLO (Thorasys Thoracic Medical System Inc., Montreal, 
Canada). It was necessary to do the FOT before the spirometry because the forced manoeuvres 
of spirometry have an impact on resistance and reactance values 21. 
The patient was sit straight on a chair with uncrossed legs, hands on cheeks to avoid any bias 
due to cheeks compliance, in order to minimize the upper airway artefact 18. Because pressure 
oscillations are applied at the mouth, there are oscillatory motion in the mouth cavity and the 
extrathoracic airways which affect the results of measurements which it is called the upper 
airway artefact. Indeed, if the cheeks are not held, R₂₀ values reduce significantly and are 
therefore underestimated. It affects also the R₅ and X₅ significantly 18 21. 
During the test, the patient wore a nose-clip and breathed through a mouthpiece. It was 
important to check that the patient putted the mouthpiece in the right way, that means that the 
mouthpiece should be entirely in the mouth and the patient’s teeth should tighten the plastic 
end thereof. Once the device and the patient were ready, the test started. The patient breathed 
normally through the pneumotachograph (tidal breathing) and when breathing was stable, 
oscillations waves were sent during 20 seconds for a run. Minimum three runs were needed and 
maximum eight runs.  
The parameters that were kept with this technique are the mean of all these measurements: the 
resistance of the respiratory system at 5 and 19 Hz (R5…19) during the entire respiratory cycle, 
the difference in resistance between 5 and 19Hz  (R5-19), the inspiratory resistance at 5Hz 
(R₅,in), the expiratory resistance at 5Hz (R₅,ex), the inspiratory resistance at 19Hz (R₁₉,in), the 
expiratory resistance at 19Hz (R₁₉,ex), the difference in inspiratory resistance between 5 and 
19Hz (R5-19,in), the difference in expiratory resistance between 5 and 19Hz (R5-19,ex), the 
reactance of the respiratory system at 5 Hz (X5) during the entire respiratory cycle, the 
resonance frequency of the respiratory system at 5 Hz (fres), area above the reactance-frequency 
curve at 5Hz up to FRes (AX5), the difference between inspiratory and expiratory reactance at 
5Hz (ΔX₅), the expiratory reactance at 5 Hz (X₅,ex), the inspiratory reactance at 5 Hz (X₅,in), 
respiratory rate (RR), the minute ventilation (VE) and tidal volume (VT).  
 
To accept a run, it was necessary to have less than 15% coefficient of variation for R₅ and AX 











b). Total lung capacity and thoracic gas volume 
For this test, the patient was sitting with uncrossed legs in a plethysmograph, wearing a nose-
clip and a mouthpiece supporting his cheeks in both hands to avoid upper airway bias, see 
previous paragraph for the explanations. The cabin door was closed and a waiting time of 1 
minute was required to allow the thermic stabilisation of the cabin. 
The patient breathed normally and when tidal breathing was stable, the shutter was closed at 
the end of an expiration. The duration of the occlusion lasting approximately 3 seconds and the 
patient continued to breathe during this one. When the shutter was reopened, the patient inspired 
deeply followed by a long and complete exhalation to the residual volume (RV) which is the 
volume of gas remaining in the lungs after forced expiration. The manoeuvre was ended by a 
maximal inspiration (to see the manoeuvre of this technique see Figure 10, Panel B). This 
manoeuvre allowed us to measure  
Figure 9. Illustration of the Tremoflo results window which stands out in three panels. The left panel represents 
the navigation plane with the different runs of measurements made. The midst panel is the impedance chart with 
following graphical parameters measured at various oscillation frequencies represented on the x-axis: the top 
curve with squares represents the resistance (R) values and the bottom curve with circles represents the reactance 
(X) values. Thin curves with represent each individual measurements of the patient. Thick curves represent 
average values acquired in different runs for R and X at various frequencies. Continuous black curves represent 
the predicted values according to the patient age, sex, height and weight and dashed lines represent the higher 
limits of normal for R and lower limit of normal for X. On the right panel, test mean values recorded in the patient 
are expressed on a green-to-red Gauge scales to easily visualize the state of a patient’s respiratory mechanics 
relative to their predicted values, the significance of the individual colours is as follows : green for measurements 
within the 95% confidence interval of normal, yellow for outcome close to the upper or lower limit of normal and 
red for outcome outside of the 95% confidence interval around normal value. The yellowed area represents the 
area above the reactance-frequency curve at 5Hz. Source: tremoFlo C-100 Airwave Oscillometry System User 
Manual  
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• the thoracic gas volume (TGV) which is the volume of intrathoracic gas measured by 
plethysmography at the time of closing of the shutter, corresponding to FRC. The TGV 
is the volume compressible gas present inside the thorax at the closing of the shutter;  
• the residual volume (RV) which is the TGV diminished by the expiratory reserve 
volume (ERV; Figure 10); 
• the total lung capacity (TLC) which is the volume of gas present in the lungs after 
maximal inspiration which is also the sum RV and vital capacity (VC) 28. 
Three to five technically satisfactory maneuvers were obtained with a maximal 5% variability 
between the 2 best measurements for TLC and TGV and maximal 5% and 150 mL variability 















c). Airway resistance  
For this test, the patient was sitting upright in the plethysmograph, to avoid the compression of 
airways, wearing a nose-clip and a mouthpiece supporting his cheeks in both hands to avoid 
bias and uncrossed legs. The cabin door was closed and a waiting time of 1 minute was required 
to allow the thermic stabilisation of the cabin. 
The patient breathed rhythmically following the operator (panting manoeuvre) while captures 
were taken with the device. Then the shutter was closed at the end of an expiration. It was 
necessary to continue breathe during this one. When the shutter was reopened, the test stopped.  
This manoeuvre allowed us to have airway resistance (RAW) which comprises the resistance 
produced by the chest wall, lung tissue and the airway, and specific airway resistance (sRAW) 
which is the product of the airway resistance and FRC. 
Figure 10. Tracing of TLC manoeuvre. Abbreviations: TLC: total lung capacity ; VC: vital capacity 
; FRC: functional residual capacity ; RV: residual volume ; ERV: expiratory reserve volume ; IC: 
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First, sRAW was evaluated through simultaneous recording of airflow and plethysmographic 
volume swing during tidal breathing. TGV was evaluated through recording of 
plethysmographic volume swing and the corresponding mouth pressure swing while the patient 
performed panting manoeuvre against a closed shutter. Then RAW was calculated as the ratio 
of sRAW/TGV 30.  
It was important to notice that due to the panting manoeuvre, TGV that was measured with this 
technique might be higher than the TGV of the previous technique. It is due to the fact that 
when a rhythm is imposed to the patient, he compensates and thus increases his TGV. 
Three to five technically satisfactory tests were have to be obtained with less than 5% of 
variation between the two best measurements 29 30. The highest reproducible of each value is 
the one that we kept. 
 
d). Inspiratory capacity 
It is preferable that slow IC (inspiratory capacity) and VC (vital capacity) manoeuvres were 
performed before FVC (forced vital capacity) manoeuvres to minimize the risk of  
• modification of small airway smooth muscle tone; 
• interference with patient fatigue induced by forced manoeuvres. 
For this test, the patient was tested in a sitting position wearing a nose-clip with no air leaks 
between the mouth and the mouthpiece. The patient started to breathe normally (tidal breathing) 
until quiet tidal breathing is stabilized, followed by an inspiratory manoeuvre to TLC to record 
IC, followed by a full expiration to RV to record the expiratory vital capacity (EVC) (see Figure 
11). The manoeuvre was not forced but the patient had to understand that he had to completely 
inflate and thereafter empty his lungs 31. This manoeuvre allowed us to have slow IC and VC 
which are respectively the maximum gas volume that can be inspired from the functional 
residual capacity (FRC) and the volume of gas mobilized at the mouth between full inspiration 










Figure 11. Tracing of IC manoeuvre. Abbreviations: TLC: total lung capacity ; FRC: functional residual capacity ; 
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Minimum three tests with acceptable values were needed and maximum eight tests were done. 
The variation of the measurements of slow IC and VC was not to be greater than 150 ml and 
5% between the two best measurements. The highest reproducible of each value is the one that 
we kept. 
 
e). Forced vital capacity  
For this test, the patient was tested in a sitting position wearing a nose-clip with no air leaks 
between the mouth and the mouthpiece. 
The manoeuvre was composed of three distinct phases, the patient first breathed normally (tidal 
breathing) then he inspired quickly and thoroughly from the functional residual capacity (FRC) 
follows by a ‘‘blast’’ of exhalation to the residual volume (RV) of minimum 6 seconds, to 
empty his lungs to the maximum. Then the patient ended with a deep inspiration (see Figure 7). 
This manoeuvre allowed us to have forced vital capacity (FVC) which is the maximum volume 
of air exhaled during a maximal effort performed from a maximum inspiration and the forced 
expiratory volume in one second (FEV₁) which is the maximum volume of air exhaled during 
the first second of a forced expiration from a maximum inspiration 28 31. 
Minimum three tests with acceptable values were needed and maximum eight tests were done. 
The difference for the FVC and FEV₁ was not to be greater than 150 ml between the two best 
measurements 31. The highest reproducible of each value is the one that we kept. 
 
f). Diffusion indices 
This test was used to measure the diffusion of carbon monoxide with the use of a gas test 
composed of carbon monoxide (CO) and a tracer gas (helium) to measure the alveolar volume 
(VA). The tracer gas should be relatively insoluble as well as chemically and biologically inert. 
Given that the tracer gas was used to determine the initial alveolar concentration of CO, as well 
as the alveolar volume from which CO diffuses, its diffusion should therefore be similar to that 
of CO. It should not influence the measurement of CO concentration. It was important that it 
does not exist naturally in the alveolar gas, that’s why helium was used as a tracer gas, because 
he fulfils the majority of these criteria. 
Concerning the method, once the mouthpiece and the nose-clip were in place, the patient 
breathed normally through the pneumotachograph (tidal breathing) and when it was stable, the 
manoeuvre started with a non-forced exhalation to the residual volume (RV). In case of COPD, 
the expiration to the residual volume may take longer time, so it will be useful to limit the 
duration of this manoeuvre to six seconds. When the residual volume was reached, the gas test 
was released and the patient inspired quickly to the total lung capacity (TLC). Then an apnoea 
of ten seconds was requested; this action was required to allow CO to diffuse from the alveolar 
compartment to the blood compartment. When the time was up, the patient performed a rapidly 
exhaled air for approximately four seconds with a collection duration of three seconds. The 
sample taken during this expiration was used to evaluate helium and CO concentrations still 
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present in the lungs. The changes in concentrations allowed us to calculate diffusion indices ; 
the CO transfer coefficient (KCO), which is the capture of pulmonary CO measured as the fall 
in alveolar CO concentration, was multiplied by the volume of gas accessible to the CO 
(alveolar volume) to obtain DLCO which is the total capacity of CO transfer. 
Two tests with a variation less than 3ml/min/mmHg were recommended with a waiting time of 
4 minutes between the tests to allow adequate elimination of test gases from the lungs. Deep 
inspirations helped eliminate gas more effectively. It was recommended that the patient remains 
seated during this waiting time. Maximum five tests were done 32. The highest reproducible of 
each value is the one that we kept. 
 
g). Bronchodilator response    
To study the bronchodilator response in this study, 4 puffs of DUOVENT HFA® 
(corresponding to 80 g of ipratropium bromide and 200 g of fenoterol hydrobromide) were 
administered using an inhalation chamber. 
A waiting time of 30 minutes was required before starting the manoeuvre previously done, 
except for the diffusion which was performed only pre-bronchodilator.  
 
3.4. Privacy and confidentiality  
Patients’ data were collected after the signature of the informed consent. The data are 
confidential and the anonymity is guaranteed. If the collected data have an interest in the 
patient's medical follow-up, the relevant data can be sent to the patient’s physician except if the 
patient disagree. 
 
3.5. Statistical analysis  
Measurements before and after bronchodilators were compared by student t-test for paired 
samples or by Wilcoxon test if the conditions of normality were not be fulfilled. To assess the 
normality, shapiro-wilk test was used. 
The following relationships were evaluated by linear regression and Pearson or Spearman 
correlation coefficient, as required: 
Changes after bronchodilators in the parameters measured by forced oscillation on the one side 
and FEV₁ and IC on the other side,  
IC and various respiratory function parameters measured after bronchodilators on the one side 
and dyspnea indices on the other side;  
The predictive character of an improvement in IC (> 10% predicted value) or an improvement 
in FEV₁ (200 mL and 12%) were determined for the bronchodilator response of various 
functional parameters with the use of the ROC method. 
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The statistical threshold of significance was set at 0.05 (two-sided test). 
All data were analysed using R-studio statistic program Version 1.1.456, with the exception of 
ROC curves which were generated using the NCSS 11 Statistical Software (version 11.0.12). 
NCSS, LLC. Kaysville, Utah, USA. 
 
4. Results  
 
4.1. Study population 
The baseline characteristics of the 26 patients involved in this study are described in table 3. 
As shown in the table, there was a majority of men. GOLD stage 2 and 3 were equally 
represented but stage 1 and 4 were underrepresented. MRC stage 2 and 3 were equally 
represented but stage 0, 1 and 4 were underrepresented. 
 
Table 3. Baseline characteristics of the patients. 
Characteristics  Value 





Age (years)  65,7 ± 7,32 
Gender (male/female)  21/5 
Smokers/Ex-Smokers  7/19 
Height (cm)  172 ± 9 
Weight (kg)  70 ± 18 
BMI (kg/m²)  23,7 ± 4,7 
GOLD classification (1/2/3/4)  1/10/11/4 
CAT score 
MRC Scale (0/1/2/3/4) 
San Diego SOBQ  
 19,5 ± 8,1 
2/1/9/9/5 
53,4 ± 29,8 
   
All values are presented as absolute numbers or mean ± SD. Abbreviations: n: number of participants; SD: 
standard deviation; BMI: body mass index ; GOLD: Global initiative for chronic obstructive lung disease ; CAT: 
COPD assessment test ; mMRC: modified Medical Research Council ; SOBQ: shortness of breath questionnaire. 
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4.2. Bronchodilator response for the respiratory function tests  
Table 4 describes the results of the respiratory function tests before and after the inhalation of 
the bronchodilator. The TGV, TLC and RV parameters were measured in 25 patients, while 
the others were measured in 26, because for one patient the plethysmograph cabin could not 
detect mouth pressure changes and therefore did not provide any data for these three 
parameters in that case. 
All the conventional respiratory tests significantly improved following the administration of 
DUOVENT HFA® except for the Tiffeneau index (p-value > 0,05). 
 
Table 4. Baseline respiratory function tests results of the patients. 
Baseline characteristics      Pre-BD 
(Mean ± SD) 
 Post-BD 
(Mean ± SD) 
p-value 
      
FEV1 (L)  
 
FEV1 (% predicted) 
 
FVC (L)  
 
FVC (% predicted) 
 
 1,19 ± 0,61 
 
41 ± 16 
 
2,94 ± 0,77 
 
81 ± 18 
 
 1,38 ± 0,62 
 
47 ± 17 
 
3,40 ± 0,79 
 










Tiffeneau (%)  
 
Tiffeneau (% predicted) 
 
VC (L)  
 
VC (% predicted) 
 
IC (L)  
 
IC (% predicted) 
 
TGV (L) (n=25) 
 
TGV (% predicted) 
 
TLC (L) (n=25) 
 
TLC (% predicted) 
 
RV (L) (n=25) 
 
RV (% predicted) 
 
RAW (cmH2O/L/S)  
 
 40 ± 13 
 
52 ± 17 
 
3,21 ± 0,83 
 
84 ± 16 
 
2,16 ± 0,55 
 
79 ± 16 
 
5,55 ± 1,38 
 
164 ± 39 
 
7,54 ± 1,35 
 
119 ± 18 
 
4,83 ± 1,39 
 
204 ± 60 
 
4,74 ± 2,19 
 
 40 ± 12 
 
52 ± 17 
 
3,52 ± 0,89 
 
93 ± 18 
 
2,37 ± 0,58 
 
86 ± 17 
 
5,00 ± 1,12 
 
149 ± 34 
 
7,22 ± 1,12 
 
114 ± 17 
 
4,03 ± 1,18 
 
171 ± 54 
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RAW (% predicted) 
 
sRAW (cmH2O*s)  
 
sRAW (% predicted) 
 
DLCO (mL/mmHg/min)  
 
DLCO (% predicted) 
 
KCO (DLCO/L)  
 
KCO (% predicted) 
368 ± 172 
 
31,5 ± 18,9 
 
726 ± 435 
 
16,7 ± 8,6 
 
52 ± 22 
 
2,79 ± 1,29 
 
58 ± 27 
 
262 ± 171 
 
22,6 ± 18,1 
 























      
All values are presented as mean ± SD. Abbreviations: SD: standard deviation ; BD: bronchodilator ; FEV1: forced 
expiratory volume in one second ; FVC: forced vital capacity ; VC: vital capacity ; IC: inspiratory capacity ; TGV: 
thoracic gas volume ; TLC: total lung capacity ; RV: residual volume ; RAW: airway resistance ; sRAW: specific 




4.3. Bronchodilator response for parameters measured by FOT  
Table 5 describes the FOT parameters before and after bronchodilator administration. All 
FOT parameters significantly improved following bronchodilator administration, except for 
R19, R19ex, ∆X5 and RR (p-value > 0.05). In contrast, the change in AX5 was highly 
significant (p-value < 0,001). 
Fres parameter was not included in the analysis because 14 COPD patients in pre-
bronchodilator test and 8 in post-bronchodilator test had a Fres superior to the higher 
frequency analysed by the Tremoflo® inducing a not applicable result. 
As said above, a ∆X5 > 2,8 was a surrogate for EFL detection. Nine patients had EFL 
according to this criterion in pre-bronchodilator condition and 9 in post-bronchodilator 
condition of whom 8 also had EFL pre-bronchodilator administration. Only one patient with 
EFL before bronchodilator became non EFL after the administration of bronchodilator. This 
patient had a good response for all the others parameters. 
As opposed to expectations, one patient without EFL in pre-bronchodilator condition 
presented EFL after the administration of DUOVENT HFA®, despite that all other 
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Table 5. Baseline and post-BD FOT parameters. 
Baseline characteristics  Pre-BD 
(Mean ± SD) 
Post-BD 
(Mean ± SD) 
p-value 
R5 (cmH₂O.s/L)  
R19 (cmH₂O.s/L)  
R5-19 (cmH₂O.s/L)  
R5,in (cmH₂O.s/L)  
R5,ex (cmH₂O.s/L)  
R19,in (cmH₂O.s/L)  
R19,ex (cmH₂O.s/L)  
R5-19,in (cmH₂O.s/L)  
R5-19,ex (cmH₂O.s/L)  
X5 (cmH₂O.s/L)  
AX5 (cmH₂O/L)  
∆X5 (cmH₂O.s/L)  
X5,in (cmH₂O.s/L)  
X5,ex (cmH₂O.s/L)  
 5,24 ± 1,62 
2,99 ± 0,96 
2,25 ± 0,81 
4,83 ± 1,46 
5,51 ± 1,82 
3,14 ± 1,01 
2,89 ± 0,95 
1,69 ± 0,66 
2,62 ± 0,99 
-4,88 ± 2,12 
57,4 ± 28,3 
2,45 ± 2,45 
-3,40 ± 1,28 
-5,85 ± 2,94 
4,71 ± 1,58 
2,88 ± 1,03 
1,83 ± 0,73 
4,04 ± 1,36 
5,17 ± 1,82 
2,94 ± 1,06 
2,84 ± 1,04 
1,10 ± 0,62 
2,33 ± 0,90 
-4,09 ± 1,78 
    44,6 ± 24,1 
2,15 ± 2,16 
-2,73 ± 1,03 















     
All values are presented as mean ± SD. Abbreviations: SD: standard deviation ; BD: bronchodilator ; R5: 
resistance at 5Hz ; R19: resistance at 19Hz  ; R5-19: difference in resistance between 5 and 19Hz ; R5in: 
inspiratory resistance at 5Hz ; R5ex: expiratory resistance at 5Hz  ; R19 in: inspiratory resistance at 19Hz ; 
R19ex: expiratory resistance at 19Hz  ; R5-19in: difference in inspiratory resistance between 5 and 19Hz ; R5-
19ex: difference in expiratory resistance between 5 and 19Hz  ; X5: reactance at 5Hz  ; AX5: area above the 
reactance-frequency curve at 5Hz ; ∆X5: difference between inspiratory and expiratory reactance at 5Hz ; X5ex: 
expiratory reactance at 5Hz ; X5in: inspiratory reactance at 5Hz ; VT: tidal volume ; RR: respiratory rate ; VE: 
minute ventilation ; NS: not significant. 
 
4.4. Correlations between the modified Medical Research Council dyspnea questionnaire 
score and respiratory function parameters 
There was no significant correlation between the different respiratory function parameters 
including those measured by FOT and the modified Medical Research Council questionnaire 
dyspnea score neither in pre-bronchodilator nor is post-bronchodilator condition. All p-values 
were superior to 0,05. 
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4.5. Correlations between the San Diego Shortness of Breath Questionnaire score and 
respiratory function parameters 
 
Table 6 describes the correlation between the respiratory parameters and the intensity of 
dyspnea assessed by the San Diego SOBQ questionnaire after the inhalation of the 
bronchodilator. There was a significant correlation with IC, RAW, R5, R5-19, R5ex, X5 and 
AX5.    
 
Table 6. Correlations between respiratory functions parameters and the intensity of dyspnea assessed by the 
San Diego SOBQ questionnaire. 
    








Respiratory parameters     




VC (L)  
 
IC (L)  
 
TGV (L)  
 
TLC (L)  
 












R5-19 (cmH₂O.s/L)  
 
R5,in (cmH₂O.s/L)  
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Abbreviations: BD: bronchodilator ; FEV1: forced expiratory volume in one second ; FVC: forced vital capacity ; 
VC: vital capacity ; IC: inspiratory capacity ; TGV: thoracic gas volume ; TLC: total lung capacity ; RV: residual 
volume ; RAW: airway resistance ; R5: resistance at 5Hz ; R5-19: difference in resistance between 5 and 19Hz ; 
R5in: inspiratory resistance at 5Hz ; R5ex: expiratory resistance at 5Hz ; X5: reactance at 5Hz  ; AX5: area above 
the reactance-frequency curve at 5Hz ; ∆X5: difference between inspiratory and expiratory reactance at 5Hz ; 
X5ex: expiratory reactance at 5Hz ; X5in: inspiratory reactance at 5Hz ; NS: not significant ; r : correlation 
coefficient. *These parameters were only measured in pre-bronchodilator condition. 
 
 




















Figure 12. Correlations between respiratory functions parameters and intensity of dyspnea assessed by 
the San Diego SOBQ questionnaire score (SANDIEG) after the bronchodilator inhalation. Abbreviations: 
FEV1POST: Post-bronchodilator Forced Expiratory Volume in one second ; ICPOST: post-bronchodilator 
inspiratory capacity ; AX5POST: post-bronchodilator area above the reactance-frequency curve at 5Hz ;  
r : correlation coefficient. 
r = -0.4394 
p-value = 0.0247 
b) 
r = 0.4114 
p-value = 0.0368 
c) 
r = -0.2981 
p-value = 0.1391 
a) 
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4.6. Correlations between the changes of inspiratory capacity and the changes of other 
respiratory function parameters after bronchodilator administration 
 
Table 7 describes the correlations between the variation of IC and the variation of the 
respiratory function parameters after bronchodilator administration. The change in VC, TGV, 
RV, R5, R5in, AX5 and X5in were significantly correlated with the change of IC. 
 
Table 7. Correlations between the change in inspiratory capacity (∆IC) and the change in respiratory function 
parameters (∆ respiratory parameters) after bronchodilator administration. 
    








∆ Respiratory parameters    




VC (L)  
 
TGV (L)  
 
TLC (L)  
 








R5-19 (cmH₂O.s/L)  
 
R5,in (cmH₂O.s/L)  
 




AX5 (cmH₂O/L)  
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Abbreviations: BD: bronchodilator ; FEV1: forced expiratory volume in one second ; FVC: forced vital capacity ; 
VC: vital capacity ; IC: inspiratory capacity ; TGV: thoracic gas volume ; TLC: total lung capacity ; RV: residual 
volume ; RAW: airway resistance ; R5: resistance at 5Hz ; R19: resistance at 19Hz ; R5-19: difference in 
resistance between 5 and 19Hz ; R5in: inspiratory resistance at 5Hz ; R5ex: expiratory resistance at 5Hz ; X5: 
reactance at 5Hz  ; AX5: area above the reactance-frequency curve at 5Hz ; ∆X5: difference between inspiratory 
and expiratory reactance at 5Hz ; X5ex: expiratory reactance at 5Hz ; X5in: inspiratory reactance at 5Hz ; NS: 
not significant ; r : correlation coefficient ; ∆IC: change in inspiratory capacity after bronchodilator 
administration; ∆ respiratory parameters: change in respiratory function parameters after bronchodilator 
administration. 
 
Figure 13 shows correlations between the change of IC and the change of respiratory function 






















Figure 13. Correlations between the change of inspiratory capacity and the change of respiratory function parameters after 
bronchodilator administration. Abbreviations: VarIC: change in inspiratory capacity ; VarRV: change in residual volume ; 
VarAX: change in area above the reactance-frequency curve at 5Hz ; VarR5: change in resistance at 5Hz ; r : correlation 
coefficient.   
r = -0.5852 
p-value = 0.0017 
b) 
r = -0.4315 
p-value = 0.0277 
c) 
a) 
r = -0.6540 
p-value = 0.0004 
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4.7. Correlations between the changes of forced expiratory volume in one second and the 
changes of other respiratory function parameters after bronchodilator administration 
 
Table 8. Correlations between the change in forced expiratory volume in one second (∆FEV₁) and the change in 
respiratory functions parameters (∆ respiratory parameters) after bronchodilator administration. 
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Abbreviations: BD: bronchodilator ; FEV1: forced expiratory volume in one second ; FVC: forced vital capacity ; 
VC: vital capacity ; IC: inspiratory capacity ; TGV: thoracic gas volume ; TLC: total lung capacity ; RV: residual 
volume ; RAW: airway resistance ; R5: resistance at 5Hz ; R19: resistance at 19Hz ; R5-19: difference in 
resistance between 5 and 19Hz ; R5in: inspiratory resistance at 5Hz ; R5ex: expiratory resistance at 5Hz ; X5: 
reactance at 5Hz  ; AX5: area above the reactance-frequency curve at 5Hz ; ∆X5: difference between inspiratory 
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and expiratory reactance at 5Hz ; X5ex: expiratory reactance at 5Hz ; X5in: inspiratory reactance at 5Hz ; NS: 
not significant ; r : correlation coefficient ; ∆FEV₁: change in forced expiratory volume in one second ; ∆ 
respiratory parameters: change in respiratory function parameters. 
 
Table 8 describes the correlations between the variation of FEV₁ and the variation of the 
respiratory function parameters after bronchodilator administration. The change in FVC, VC, 
R5, R5-19, R5in, AX5 and X5in were significantly correlated with the change in FEV₁. 
Figure 14 shows correlations between the changes of FEV₁ and the change of respiratory 

























Figure 14. Correlations between the change in forced expiratory volume in one second and the change in respiratory 
function parameters. Abbreviations: VarFEV1: change in forced expiratory volume in one second ; VardelX5 : Variation of 
the difference between inspiratory and expiratory reactance at 5Hz ; VarAX: change in area above the reactance-frequency 
curve at 5Hz ; VarVC: change in vital capacity ; VarFVC: change in forced vital capacity ; r : correlation coefficient. 
r = -0.4750 
p-value = 0.0142 
b) 
r = -0.2929 
p-value = 0.1465 
a) 
r = 0.4850 
p-value = 0.0120 
c) d) 
r = 0.5791 
p-value = 0.0019 
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Figure 15 represents ROC curve for the evaluation of the prediction of a 10% improvement in 
IC from changes in vital capacity parameters after bronchodilator administration.  
Table 9 describes the different values of the ROC-AUC and p-values. As can be seen, the 
variation of TGV, sRAW and VC were predictors of a 10% predicted improvement in IC. 
                                    Table 9. AUC for ROC curves and p-value results of the figure 15. 
Parameters AUC p-value 
TGV 0,74 <0,05 
TLC 0,66 NS 
RAW 0,68 NS 
sRAW 0,80 <0,001 
VC 0,82 <0,001 
FVC 0,63 NS 
FEV1 0,62 NS 
FEV1/FVC 0,61 NS 
   
   
Abbreviations: AUC: area under the curve ; TGV: thoracic gas volume ; TLC: total lung capacity ; RAW: airway 
resistance ; sRAW: specific airway resistance ; VC: vital capacity ; FVC: forced vital capacity ; FEV1: forced 
expiratory volume in one second. 
 
Figure 15. ROC curve for the prediction of an improvement of 10% predicted in IC. Curve represents this 
evaluation with the change in slow vital capacity after bronchodilator administration. Abbreviations: 
ROC: receiver operating characteristic ; IC: inspiratory capacity.  
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Figure 16 represents the ROC curve for the evaluation of the prediction of a 10% predicted 
improvement in IC from changes in area above the reactance-frequency curve at 5Hz after 

















                                   Table 10. AUC for ROC curve and p-value results of the figure 16. 
Parameters AUC p-value 
X5 0,59 NS 
X5,in 0,59 NS 
X5,ex 0,69 <0,05 
R5 0,69 <0 ,05 
R5,in 0,75 <0,01 
R5,ex 0,58 NS 
R19 0,59 NS 
R19,in 0,61 NS 
R19,ex 0,60 NS 
R5-19 0,68 <0,05 
R5-19,in 0,72 <0,05 
R5-19,ex 0,59 NS 
AX5 0,80 <0,01 
∆X5 0,49 NS 
Figure 16. ROC curves for the prediction of an improvement of a 10% predicted in IC. Curve represents this 
evaluation with the changes in area above the reactance-frequency curve at 5Hz after bronchodilator 
administration. Abbreviations: ROC: receiver operating characteristic ; IC: inspiratory capacity. 
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Abbreviations: AUC: area under the curve ; X5: reactance of the respiratory system at 5Hz ; X5ex: expiratory 
reactance at 5Hz ; X5in: inspiratory reactance at 5Hz ; R5: resistance of the respiratory system at 5Hz ; R19: 
resistance of the respiratory system at 19Hz ; R5-19: difference in resistance between 5 and 19Hz ; R5in: 
inspiratory resistance at 5Hz ; R5ex: expiratory resistance at 5Hz ; R19in: inspiratory resistance at 19Hz ; R19ex: 
expiratory resistance at 19Hz ; R5-19in: difference in inspiratory resistance between 5 and 19Hz ; R5-19ex: 
difference in expiratory resistance between 5 and 19Hz ; AX5: area above the reactance-frequency curve at 5Hz 
; ∆X5: difference between inspiratory and expiratory reactance at 5Hz. 
 
Table 10 describes the different values of AUC and p-value of the figure 16. As can be seen, 
the variation of X5ex, R5, R5in, R5-19, R5-19in and AX5 were significant predictors of an 
improvement of 10% predicted in IC.  
 
 
5. Discussion  
Assessing the response to bronchodilator in COPD patients is supposedly important for 
adapting the bronchodilator therapy in patients with COPD in order to control dyspnea as best 
as possible. However, the relationship between FEV₁ and dyspnea has been shown to be poor. 
Accordingly, we were interested in studying  
• the relationship between dyspnea and forced oscillation parameters; 
• the relationship between the bronchodilator response of these parameters with that of 
FEV₁ and IC, a parameter that has been shown to be more closely related to dyspnea; 
• the predictors of a clinically meaningful improvement in IC (10% predicted increase) 
after bronchodilation 33 . 
 
In the following discussion, we will discuss the results of the present study. First of all, we will 
discuss about the assessment of the bronchodilator response after the inhalation of DUOVENT 
HFA®. This part of the discussion will be subdivided in two different points, the first one will 
be about the conventional respiratory function parameters and the second about the FOT 
parameters, including resistance and reactance parameters.  
The second part of the discussion concerns the correlation between intensity of dyspnea, 
respiratory function parameters and FOT parameters. 
Thirdly, we will discuss about the correlation between variation of IC and variation of 
respiratory function parameters. The fourth part will talk the correlation between variation of 
FEV₁ and variation of respiratory function parameters as this is still the most used criteria to 
assess the bronchodilator response in pulmonary function labs. 
Finally, we will finish this discussion with the parameters that can predict a clinically 
meaningful improvement in inspiratory capacity. 
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5.1. Assessment of the bronchodilator response 
 
5.1.1. Conventional respiratory function 
As expected, the effects of the short-acting bronchodilator administration that we observed in 
the present study were similar to those reported in other studies 3 25 34. Indeed, mean values of 
classical pulmonary function tests parameters, FEV₁, %FEV1, FVC, %FVC, VC, %VC, IC, 
%IC, TGV, %TGV, TLC, %TLC, RV, %RV, RAW, %RAW, sRAW and %sRAW were 
significantly improved after the DUOVENT HFA® inhalation (see table 4). 
 
Bronchodilator inhalation induced a highly significant increased FEV₁ and FVC but no change 
for the Tiffeneau index which was concordant with previous studies 34 35. The increase in VC 
is associated with a decreased RV, which is related to a reduction in air trapping after 
bronchodilator administration. The improvement in FEV₁ is related to an improvement in large 
airways resistance, as well as in airway resistance from alveolar units with rapid time constants 
for lung emptying.  
 
Because bronchodilators induce rapid relaxation of airway smooth muscle and thus increase 
airway calibre, it was expected to observe a reduction in RAW and sRAW 17.  
The significant increased IC and decreased FRC extended results of previous studies 35. 
This decrease in FRC means reduced EELV, it allows patients to do exercise for longer time 
before dynamic hyperinflation reaches the critical point where the inspiratory reserve decreases 
inducing intolerable dyspnea 17. The reduced FRC which also explains an increase in IC is the 
main reason for the relief of dyspnea after bronchodilator administration. 
Conventional respiratory function cannot measure easily the improvement of small airways. 
But reduced lung volumes is a consequence of enhanced gas emptying in the alveolar units with 
slower mechanical time constants providing indirect evidence of a positive effect of the 
DUOVENT HFA® on small airway function 12. 
 
5.1.2. Forced oscillation technique 
Usually, bronchodilator effect is assessed by the changes in FEV₁. But thanks to its many 
advantages, FOT, is an attractive tool to evaluate the response to bronchodilator 36. Moreover, 
FOT is able to assess the improvement in small airway function induced by bronchodilatation 
and may thus give additional information as compared to conventional respiratory function 
tests. 
In this study, we were particularly interested about the reactance parameters which have been 
relatively forgotten as compared to the resistance parameters in the literature.  
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The changes after the inhalation of bronchodilator for the FOT parameters are shown in table 
5. 
  
5.1.2.1. Resistance  
Means values of FOT parameters R5, R5-19, R5in, R5ex, R19in, R5-19in and R5-19ex were 
significantly improved after the bronchodilator inhalation (see table 5). This is coherent with 
those of the literature  17 36 37.  
Compared to conventional respiratory function test, FOT gives information about the small 
airways. Indeed, R5 represents total airway resistance and R19 the resistance of the upper 
airways. Subtracting R19 from R5 (R5-19) provides an assessment of small airway resistance 
21 23. As we know, small airways are the most impacted in COPD as discussed in the 
introduction. As we can see, R5 values were much higher than R19 values meaning an increased 
small airway resistance.  
As can be seen in table 5, inhaled bronchodilators decrease both total and small airways 
resistance significantly. But conversely, no significant decrease for the R19 parameter. This 




The changes in reactance parameters observed after bronchodilator administration in the present 
study were also in accordance with the literature 27 34 37. Mean values of X5, AX5, X5in, X5ex 
were significantly improved (i.e. became less negative) after bronchodilator administration (see 
table 5). Given that reactance values reflect the elastic properties of the system and that elastic 
properties are correlated with the small airways, reactance values are correlated with small 
airways. Thus, a decrease in AX5 and an increase in X5 means that we had an improvement in 
small airways function. Less negative reactance values mean that there was a decrease of the 
hyperinflation and thus improvement of dyspnea. In others words, less negative reactance 
values mean that the disease became less severe  20 21. 
On the other hand, the parameter ∆X5 didn’t improve significantly as opposed to our initial 
study hypothesis. This result is in accordance with a recent study directed by Stephen Milne at 
al 3. In parallel only one patient experienced a relief of tidal respiration EFL according to the 
criteria of Dellacà after bronchodilation 38 39. This means that despite the improvement in 
maximal expiratory flows, tidal EFL probably rarely disappear after bronchodilator 
administration in COPD. Accordingly, changes in ∆X5 are not sensitive to the effect of 
bronchodilators in COPD. 
However, the present study suggests that other reactance parameters change after 
bronchodilator administration could be of interest. For example, AX5 (the area above the 
reactance-frequency curve) showed dramatic improvement. As discussed in the literature, 
changes in AX5 are correlated to the changes in the degree of peripheral airway obstruction 
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thus it is correlated to R5-19 21. The highly significant decrease in AX5 (p<0,001) show that 
there is a decrease in peripheral airways obstruction after the administration of the 
bronchodilator inducing an improvement of dyspnea. Moreover, as discussed below, AX5 was 
correlated with dyspnea and the changes in AX5 after bronchodilator administration were 
correlated with those of IC. 
As described in the literature, expiratory reactance as well as resistance parameters were more 
severely impaired in the expiratory than the inspiratory part of the breathing cycle (see table 5) 
25 40. This is due to a higher pleural pressure in expiration explaining a reduced small airway 
diameter at a given lung volume in the expiratory phase of the breathing cycle. Higher reactance 
might be explained by the presence of EFL in expiration rather than in inspiration. The 
improvement of parameters measured during inspiration appeared to be higher than those 
measured in expiration after the administration of the bronchodilator. This was particularly true 
for R5 and R5-R19. This might suggest that the changes in the bronchial smooth muscle tone 
have more effect on the airway diameter in the inspiratory phase. 
 
5.2. Correlation between intensity of dyspnea, conventional respiratory function and FOT 
parameters  
Two questionnaires were used to evaluate the correlation between the intensity of dyspnea and 
the different respiratory parameters in this study: the mMRC questionnaire and the San Diego 
SOBQ. We will discuss both. 
We only analysed the correlations in post-bronchodilator condition as these instruments assess 
dyspnea in the daily life. We indeed postulated that in the daily life, patients are under the 
influence of the bronchodilators with which they are treated on a regular basis. 
 
5.2.1. mMRC questionnaire 
This study could not find any correlation between the intensity of dyspnea assessed by the 
mMRC questionnaire and pulmonary function test parameters. This might be due to the fact 
that this questionnaire is only a 5 scale score not very sensitive to changes in dyspnea intensity. 
This probably explains the fact that a majority of the patients complained of a mMRC dyspnea 
score of 2 or 3 on this scale. 
 
5.2.2. San Diego shortness of breath questionnaire  
Previous study showed that this questionnaire was a valuable tool to assess dyspnea 41. We 
found some correlations between the intensity of dyspnea assessed by the San Diego SOBQ 
questionnaire and pulmonary function parameters. This questionnaire appeared to be more 
discriminant for the assessment of dyspnea intensity. This can be due to the fact that it was 
more extensive. The dyspnea on this scale scores had a more widespread distribution and thus 
was more exploitable. 
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As can be seen in table 6, dyspnea assessed by the San Diego SOBQ significantly correlated 
with R5, R5ex, IC, X5, RAW, R5-19 and AX5. 
 
In accordance with the literature, we found a significant correlation between the dyspnea score 
and IC but no correlation with FEV₁ (see figure 12) 26. Interestingly, Boni et al. also showed 
that changes in IC after bronchodilators in patients with COPD and EFL were strongly 
correlated with an improvement of dyspnea, even in the absence of a significant increase in 
FEV₁ 33. Other studies also demonstrated a significant association between improvements in 
dyspnea and the increase in IC following bronchodilator administration 35 42. The present study 
confirmed that IC is more closely related to dyspnea than FEV₁.  
We also found a correlation between FOT parameters and dyspnea. All these parameters are 
thought to be related to small airway function. According to our knowledge, this study is the 
first to show a significant correlation between FOT parameters and dyspnea. 
 
5.3. Correlation between variation of inspiratory capacity and variation of respiratory 
function parameters 
Given there is a strong correlation between IC and dyspnea as well as between changes in IC 
and changes in dyspnea, we wanted to assess the correlation between changes in IC and those 
of various respiratory function parameters after bronchodilator administration in order to 
propose clinically useful parameters to assess during a bronchodilator test. 
We found that the strongest correlation with variation of IC was the variation of RV (p-value 
<0,001) (see table 7-figure 13 A). This could be expected since both an increase in IC and a 
reduction in RV reflect reduced air trapping and lung hyperinflation 3.  
The finding of a significant association between the changes of IC and those of AX5 and R5 is 
interesting (see table 7-figure 13 B-C). Milne et al. had shown that the changes in hyperinflation 
described in their study as ∆(RV/TLC) was highly significantly correlated with the changes in 
AX5 reinforcing our results. They also shown a significant correlation between changes in 
hyperinflation with changes in R5 like we have found 3. 
Our results were concordant with those of the study of Milne et al., with the difference that we 
had more patients recruited and including more severe cases.  
However, we could not find any correlation with the changes in FEV₁, suggesting that IC and 
FEV₁ reflect different aspects of airway function.  
The association however was not strong, the changes in FOT parameters explaining less than 
35% of the changes in IC. 
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5.4. Correlation between variation of forced expiratory volume in one second and variation 
of respiratory function parameters 
The strongest correlation between variation of FEV₁ was with the variation of FVC (p-value 
<0,01) (see table 8-figure 14 D).  
Although we also found some association between changes in FEV₁ and changes in FOT 
parameters, the association was weaker than for the association with the changes in IC (see 
table 7 and table 8). 
 
5.5. Prediction of clinically meaningful improvement in inspiratory capacity  
Given that correlation between IC and dyspnea. It was logical to determine which parameters 
could be predictor of an improvement of IC and thus a predictor of an improvement of dyspnea. 
The predictors of an improvement of 10% for the IC were determined by ROC curves. The 
reason for this improvement threshold was determined by previous studies. Indeed, Boni et al., 
showed that for patients with an increase in IC greater than 10% of the predicted value, there 
was a significant decrease in exertional dyspnea, owing to a decreased EELV allowing for an 
improved exercise endurance 33 35.  
This study suggested that some changes observed after bronchodilator administration can 
predict a significant increase in IC. 
Two parameters were particularly accurate predictors: the changes in VC (AUC=0,82, p-value 
<0,001) for the conventional parameter and AX5 (AUC=0,80, p-value <0,01) for the FOT 
parameters (see figure 15 and 16). As the AUC of the ROC curve for AX5 was superior to 0,70, 
it can be considered as a good predictor for a significant improvement in IC 43. AX5 appears 
particularly interesting as it can be measured during tidal breathing and without any forceful 
maneuver, as opposed to IC or VC.  
As opposed to our initial hypothesis, ∆X5 was not a predictor for a significant improvement in 
IC (see table 10). 
 
6. Study limitations 
This study had some limitations. First of all, the Tremoflo® was sometimes very sensitive hence 
the need to repeat the manoeuvres several times.  
Secondly, this study only analysed 26 patients which is a small cohort and the results presented 
should be confirmed in a larger cohort. 
Still regarding patient limitations, the length of the tests could also influence the results. Indeed, 
some of these 26 patients have lost patience and therefore gave poorer results as the length of 
tests increased. It is also important to notice that for some patients it was difficult to stay in the 
plethysmograph, they could also provide poorer results, which reinforces the potential for the 
use of FOT, which does not require any unusual breathing maneuver. 
Assessing bronchodilator response in COPD using FOT                          
47 
 
Another limitation was the calculation of the Fres and AX5 parameters because in some cases, 
the Fres was upper than 37 Hz (the upper frequency sent by the Tremoflo®), thus the program 
could not exactly determine it. Although this somewhat impacted the calculation of the AX5, it 
does not preclude this index to increase when Fres increased above the frequency allowed by 
the Tremoflo®. 
We did not assess the reproducibility of the bronchodilation response of the FOT parameters, 
which is a limitation of the present work. It is known that the day to day reproducibility of 
bronchodilator response assessed by changes in FEV₁ is poor 17. This latter is not knowing for 
FOT parameters in COPD patients. Therefore, it would be important to evaluate it as we 
would like to use this test to assess improvement of dyspnea after bronchodilator 
administration in clinic practice. 
 
 
7. Conclusion and perspectives 
This study evaluated the bronchodilator response after the administration of DUOVENT 
HFA®. It compared this response both with conventional respiratory function tests and FOT 
parameters. 
This study suggests that FOT parameters can be useful in the assessment of the bronchodilator 
response.  This is particularly true for AX5, a parameter that has been shown to be associated 
with small airway function. It appears to be a promising index since we found that it was 
related to dyspnea and IC and that the changes in AX5 after bronchodilator administration 
were related to those of IC and were a good predictor of significant changes in IC. 
These results need to be confirmed in a larger cohort. Moreover, the reproducibility of 
changes in FOT parameters after bronchodilatation needs to be assessed. 
In conclusion, according to its ability to assess small airway function, FOT gives additional 
information as compared to conventional respiratory function. Since FOT has several 
advantages compared to other techniques, particularly its ease of use and minimal patient 
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I. Information essentielle à votre décision de participer  
Introduction : 
Vous êtes invité à participer à une étude clinique destinée à évaluer l’intérêt de la technique des 
oscillations forcées pour évaluer la réponse aux bronchodilatateurs chez les patients atteints de 
bronchopneumopathie chronique obstructive (BPCO). 
 
Le médecin investigateur espère que cette étude clinique pourra apporter  
• une meilleure définition des paramètres utiles à évaluer lors d’un test de bronchodilatation  
• une meilleure compréhension des liens entre l’effet des bronchodilatateurs sur l’essoufflement 
et sur les tests respiratoires. 
 
Avant que vous n’acceptiez d’y participer, nous vous invitons à prendre connaissance de ses 
implications en termes d’organisation, avantages et risques éventuels (dans le cas de cette étude il n’y 
a pas de risque significatif si vous bénéficiez déjà d’un traitement bronchodilatateur), afin que vous 
puissiez prendre une décision en toute connaissance de cause. Ceci s’appelle donner un 
« consentement éclairé ».  
Veuillez lire attentivement ces informations et poser toutes les questions que vous souhaitez à 
l’investigateur ou à la personne qui le représente. Ce document comprend 3 parties : l’information 
essentielle à votre prise de décision, votre consentement écrit et des informations complémentaires 
(annexes) qui détaillent certaines parties de l’information de base. 
Si vous participez à cette étude clinique, vous devez savoir que : 
• Cette étude clinique est mise en œuvre après évaluation par un comité d’éthique.  
• Votre participation est volontaire et doit rester libre de toute contrainte. Elle nécessite la 
signature d’un document exprimant votre consentement.  Même après l’avoir signé, vous pouvez 
Évaluation de la pertinence de la technique des oscillations forcées 
pour évaluer la réponse aux bronchodilatateurs chez des sujets  
souffrant de BPCO. 
 
 
Promoteur de l’étude : Professeur Eric Marchand URPhyM Faculté de Médecine- 
UNamur. Rue de Bruxelles, 61 5000 Namur - Service de Pneumologie CHU-UCL- 
Namur Site de Godinne 1, Avenue du Docteur Therasse 5530 Yvoir. 
 
Comité d’éthique Médicale : CHU-UCL Namur 
 
Médecins investigateurs locaux :  Professeur Eric Marchand.  
Laboratoire de Physiologie respiratoire, URPhyM, Faculté de Médecine-UNamur. 
Rue de Bruxelles, 61, 5000 Namur. 
Service de Pneumologie, CHU-UCL-Namur, Site de Godinne Avenue du Docteur 
Therasse,1, 5530 Yvoir. 
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arrêter de participer en informant le médecin investigateur. Votre décision de ne pas ou de ne plus 
participer à l’étude n’aura aucun impact sur la qualité de vos soins ni sur vos relations avec le 
médecin investigateur. 
• Les données recueillies à cette occasion sont confidentielles et votre anonymat est garanti lors 
de la publication des résultats. 
• Une assurance a été souscrite au cas où vous subiriez un dommage lié à votre participation à 
cette étude clinique. 
• Aucun frais supplémentaire ne vous sera facturé pour les visites, examens ou traitements dans 
le cadre de cette étude. Par facilité cependant, votre participation vous sera sans doute proposée 
en lien avec un rendez-vous de consultation prévu. Dans ce cas, les honoraires liés à la 
consultation et aux examens liés à celle-ci seront facturés et pris en charge par votre mutuelle de 
manière habituelle. 
• Vous pouvez toujours contacter le médecin investigateur ou un membre de son équipe si vous 
avez besoin d’informations complémentaires.  
• Il se pourrait qu’à l’avenir, des données recueillies au cours de cette étude puisse être d’intérêt 
pour une analyse relative à une ou plusieurs autres études scientifiques. Nous vous demandons 
sur le formulaire de consentement votre accord pour cette utilisation ultérieure des données. Si les 
données relatives à votre participation devaient être analysées par des personnes tierces aux 
investigateurs de la présente étude, elles seraient transmises de manière strictement anonyme. 
 
Un complément d’informations sur vos « Droits de participant à une étude clinique » est fourni en 
annexe. 
 
Objectifs et description du protocole de l’étude : 
 
Nous vous proposons de participer à une étude clinique portant sur l’évaluation de la pertinence de 
la technique des oscillations forcées pour évaluer la réponse aux bronchodilatateurs chez des 
sujets souffrant de BPCO qui devrait inclure entre 20 à 80 patients. L’étude est menée uniquement 
au CHU-UCL-Namur. 
 
Le but est d’évaluer :  
 
• L'objectif principal de l’étude est d'évaluer si les mesures de la fonction pulmonaire enregistrés 
en respiration normale avec la TOF sont capables de prédire un effet sur la distension du 
poumon après l'administration d'un. 
• En outre, les autres objectifs de la présente étude sont les suivants: 
o comparer la capacité des mesures par TOF à prédire une réduction de la distension des 
poumons après l'administration d'un bronchodilatateur avec celle de mesures plus 
classiques de la fonction pulmonaire; 
o comparer la variation de la distension des poumons induite par l'administration d'un 
bronchodilatateur avec les modifications induites pour d'autres mesures de fonction 
respiratoire par TOF et mesures plus classiques de la fonction pulmonaire; 
o évaluer la relation entre l'efficacité du traitement bronchodilatateur perçue par le patient et 
divers paramètres des tests respiratoires. 
o évaluer la relation existant entre essoufflement et divers paramètres des tests respiratoires, 
en particulier mesurés par TOF. 
 
Les critères d’inclusion dans l’études sont : 
 
• Diagnostic clinique de BPCO confirmé par les tests fonctionnels respiratoires  
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• Tabagisme ancien ou actif (un minimum est requis). 
• Age > 40 ans. 
• Consentement éclairé. 
 
Les critères d’exclusion de l’étude sont : 
 
• Incapacité à effectuer les tests d’EFR; 
• Besoin d'oxygénothérapie continue; 
• Glaucome à angle fermé; 
• Antécédent de rétention urinaire; 
• Grossesse. 
 
Déroulement de l’étude :  
Si vous remplissez les critères pour être inclus dans l’étude et acceptez de participer à l’étude, vous 
serez soumis aux tests et examens décrits ci-dessous. 
Votre participation se fera au cour d’une seule et unique visite d’une durée de environ 1h30 à 2h00 
au cours de laquelle nous vous pèserons, mesurerons. De brefs questionnaires relatifs à votre 
essoufflement vous seront soumis avant les mesures respiratoires. 
Il vous sera demandé de suspendre vos traitements bronchodilatateurs inhalés pour minimum 6 à 24 
heures (selon le type de bronchodilatateur utilisé) avant les mesures. 
Si vous êtes fumeur, il vous sera également demandé de ne pas fumer dans les 4 heures précédant la 
visite consacrée à l’étude. 
1. Mesures par technique des oscillations forcées 
Les mesures seront réalisées à l’aide d’un appareil qui permet de générer un train de petites ondes de 
pressions à peine perceptible et, ainsi, de mesurer l’obstacle que représente votre système respiratoire 
à la pénétration des ondes à l’intérieur de celui-ci. Les mesures sont effectuées lorsque vous respirez 
normalement par la bouche à travers le système, sans effort particulier, nez occlus par un pince-nez 
pour éviter les fuites d’air, les joues soutenues par les mains (les vôtres ou celles d’un opérateur afin 
de réduire l’influence de l’élasticité des joues sur les mesures réalisées). L’appareil enregistre divers 
paramètres liés à votre respiration et aux modifications très discrètes induites par la vague de petites 
ondes de pression qu’il génère. 
 
2. La spirométrie 
Cet examen très simple permet la mesure des volumes et des débits pulmonaires. Il consiste à souffler 
dans une embout relié à un capteur. Celui-ci permet, en fonction de la "puissance" de votre souffle, 
d'enregistrer à la fois la "capacité" de votre poumon (c'est-à-dire le volume d'air que vos poumons 
peuvent inspirer et expirer) et le débit de votre souffle (c'est-à-dire le volume maximum d'air que vous 
pouvez expirer en une seconde = VEMS). 
Pour éviter les fuites d'air, on place préalablement un pince-nez. La manœuvre consiste à respirer 
normalement dans l'embout, puis au signal, de prendre une inspiration profonde et maximale, suivie 
d'une expiration complète et rapide en vidant le plus vite et le plus complètement possible vos poumons. 
Trois manœuvres acceptables au moins sont réalisées dans chaque position. Si vous souffrez de 
BPCO, vous êtes habitués à ce test qui est le plus fréquemment réalisé au laboratoire d’épreuves 
fonctionnelles respiratoires. 
 
3. La pléthysmographie 
C'est un examen quasiment similaire au précédent sauf qu'il se passe dans une cabine en verre. Il 
permet la mesure du volume d'air qui reste dans vos poumons à la fin d’une expiration et des résistances 
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bronchiques. Plus les bronches sont réduites de calibres et plus leur résistance à l'écoulement de l'air 
est augmentée. 
Cette mesure nécessite la fermeture hermétique de la porte de la cabine. La communication entre vous 
et le technicien se fait alors par l'intermédiaire d'un microphone. 
Comme pour la spirométrie, on place un embout buccal et un pince-nez afin d'éviter les fuites d'air lors 
de l'expiration. Le technicien vous demande alors d'effectuer les manœuvres d'inspiration et 
d'expiration. L'appareil enregistre alors les résistances puis les volumes d’air persistant dans le poumon 
en fin d’expiration en bloquant une fraction de seconde l'inspiration ou l'expiration. Deux mesures au 
moins seront réalisées. 
 
L’ensemble des données et mesures recueillies le seront soit par le médecin investigateur, soit par un 
représentant (infirmière de recherche) ou mémorant-e (étudiant-e en Master de Sciences biomédicales), 
formés aux techniques de fonction respiratoire, sous la responsabilité du médecin investigateur. 
 
Risques liés à votre participation à l’étude : 
 
Les examens tels que proposés dans cette étude ne présentent aucun risque significatif pour la santé. 
Vous pouvez ressentir un peu d’essoufflement après une spirométrie mais l’examen ne comporte pas 
de risque particulier dans les conditions d’inclusion de l’étude. 
La technique des oscillations forcées est encore moins susceptible de générer d’effets indésirables car 
elle ne nécessite aucune manœuvre particulière. Vous ressentirez à peine les modifications de pression 
générées par l’appareil au niveau de la bouche. Il faut insister sur le fait que l’onde de pression est liée 
à la compression de l’air ambiant, il ne s’agit nullement d’ondes toxiques ou dangereuses ; aucune 
substance étrangère ou autre agent n’est introduit dans vos voies respiratoires lors de ces mesures par 
oscillations forcées. 
L'administration de DUOVENT est le plus souvent très bien tolérée et induit même habituellement une 
diminution de l’essoufflement. Il s’agit d’un médicament habituellement recommandé dans le traitement 
de la BPCO. De rares effets secondaires peuvent toutefois survenir: augmentation de la fréquence 
cardiaque, tremblements, sécheresse de bouche pour citer les plus fréquents. Le DUOVENT est 
déconseillé en cas de glaucome (un type de glaucome seulement) et de problèmes sérieux de prostate 
qui sont des critères d’exclusion à la participation dans l’étude. 
 
Bénéfices :  
Vous ne devez pas attendre d’autres bénéfices que la satisfaction d’avoir participé à une meilleure 
compréhension de certains aspects de votre fonction respiratoire ou de votre maladie. 
 
Retrait de l’étude : 
Attention : Il y a lieu de distinguer « retrait de l’étude » et « retrait du consentement ». 
Retrait de l'étude signifie simplement que le patient arrête sa participation avant que l’ensemble des 
mesures aient été réalisées. 
Cela ne veut pas dire qu'il retire son consentement à l’analyse des données collectées. 
Retrait du consentement à l'étude signifie effectivement retirer son consentement à sa participation 
à l'étude sans justification à donner et cela peut vouloir dire retirer son consentement au traitement 
des données recueillies dans le cadre de l’étude.  
 
Votre participation est volontaire et vous avez le droit de vous retirer de l’étude pour quelque raison 
que ce soit, sans devoir vous justifier. Néanmoins, le médecin investigateur ou son représentant vous 
demanderont si vous consentez à l’analyse des données jusque-là recueillies.   




Si vous participez à cette étude clinique, nous vous demandons :  
• De collaborer pleinement au bon déroulement de cette recherche. 
• De ne masquer aucune information relative à votre état de santé, aux médicaments que vous 
prenez ou aux symptômes que vous ressentez. 
 
Vous devez également savoir que les données recueillies au cours de cette étude pouvant être 
d’intérêt pour votre suivi médical, les éléments pertinents seront transmis à votre médecin traitant sauf 
si vous y opposez. 
Contact :  
Si vous avez besoin d’informations complémentaires, mais aussi en cas de problème ou d’inquiétude, 
vous pouvez contacter le médecin investigateur (Marchand, Eric) au numéro de téléphone suivant : 
081/ 72 43 43 ou 081/ 42 33 61 ou un membre de son équipe de recherche (Boulanger, Sarah) au 
numéro de téléphone suivant (081/ 72 43 05).   
 
Si vous avez des questions relatives à vos droits de participant à une étude clinique, vous pouvez 
contacter le médiateur des droits du patient de votre institution (Madame Brigitte Malhomme) via le 
numéro de téléphone: 081 / 42 30 30.  Si nécessaire, ce dernier peut vous mettre en contact avec le 
comité d’éthique.  
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1. Je déclare que j’ai été informé sur la nature de l’étude, son but, sa durée, les éventuels 
bénéfices et risques et ce que l’on attend de moi. J’ai pris connaissance du document 
d’information et des annexes à ce document. 
2. J’ai eu suffisamment de temps pour y réfléchir et en parler avec une personne de mon choix 
comme mon médecin généraliste ou un membre de ma famille. 
3. J’ai eu l’occasion de poser toutes les questions qui me sont venues à l’esprit et j’ai obtenu une 
réponse satisfaisante à mes questions. 
4. J’ai compris que ma participation à cette étude est volontaire et que je suis libre de mettre fin 
à ma participation à cette étude sans que cela ne modifie mes relations avec l’équipe 
thérapeutique en charge de ma santé.  
5. J’ai compris que des données me concernant seront récoltées pendant toute ma participation 
à cette étude et que le médecin investigateur et le promoteur de l’étude se portent garant de 
la confidentialité de ces données.   
6. Je donne mon accord pour que les données récoltées au cours de cette étude soient utilisées 
de façon anonyme dans le cadre d’autre études concernant les mesures d’oscillations forcées 
ou la BPCO. Dans le cas inverse, veuillez biffer le point 6. 
 
Votre médecin traitant sera informé des résultats des résultats des tests respiratoires conventionnels 
(spirométrie), sauf objection de votre part. 
 
J’ai reçu une copie de l’information au participant et du consentement éclairé. 
 




Médecin investigateur :  
 
Je soussigné, Marchand Eric médecin investigateur confirme avoir fourni oralement les informations 
nécessaires sur l'étude et avoir fourni un exemplaire du document d’information au participant.  
Je confirme qu'aucune pression n'a été exercée pour que le patient accepte de participer à l'étude et 
que je suis prêt à répondre à toutes les questions supplémentaires, le cas échéant. 
Je confirme travailler en accord avec les principes éthiques énoncés dans la dernière version de la 
« Déclaration d’Helsinki », des « Bonnes pratiques Cliniques » et de la loi belge du 7 mai 2004, 
relative aux expérimentations sur la personne humaine. 
 
     Nom, prénom, Date et signature                                       Marchand Eric, Date et signature 
     du représentant de l’investigateur :                                        du médecin investigateur : 
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Informations complémentaires  
1 : Compléments d’informations sur l’organisation de l’étude : 
 
Si vous décidez de participer à cette étude, l’entièreté des examens ou procédures à l’étude sont à 
charge du promoteur.  
 
Le médecin investigateur et ses collaborateurs seront les seuls à analyser vos données. Si, plus tard, 
ces données devaient être utilisées dans le cadre d’autres études, le médecin investigateur s’engage à 
les coder de manière à ce que vous ne puissiez pas être identifié. (votre identité sera remplacée par un 
code d’identification dans l’étude)  
 
L’investigateur est responsable de la collecte des données recueillies par tous les investigateurs 
participant à la recherche, de leur traitement et de leur protection en conformité avec les impératifs de 
la loi belge relative à la protection de la vie privée.  
 
Le promoteur utilisera les données collectées, si besoin, dans le cadre de l’étude à laquelle vous 
participez mais souhaite également pouvoir les utiliser dans le cadre d’autres recherches concernant 
la même maladie que la vôtre et la technique des oscillations forcées. Toute utilisation de vos 
données en dehors du contexte décrit dans le présent document ne pourrait être menée qu’après 
approbation du comité d’éthique. 
Assurance : 
Toute participation à une étude clinique comprend un risque aussi petit soit-il.  Le promoteur assume, 
même en l’absence de faute, la responsabilité du dommage causé au participant (ou en cas de décès, 
à ses ayants-droit) et lié de manière directe ou indirecte à sa participation à la recherche. Le 
promoteur a souscrit un contrat d'assurance de cette responsabilité. 
Évaluation de la pertinence de la technique des oscillations forcées 
pour évaluer la réponse aux bronchodilatateurs chez des sujets  
souffrant de BPCO . 
 
 
Promoteur de l’étude : Professeur Eric Marchand URPHyM Faculté de Médecine- 
UNamur Rue de Bruxelles, 61 5000 Namur, Service de Pneumologie CHU-UCL- 
Namur Site de Godinne 1, Avenue du Docteur Therasse 5530 Yvoir. 
 
 
Organisme de recherche : NA 
 
Comité d’éthique Médicale : CHU-UCL Namur 
 
Médecins investigateurs locaux :  Professeur Eric Marchand.  
Laboratoire de Physiologie respiratoire, URPhyM, Faculté de Médecine-UNamur. 
Rue de Bruxelles, 61, 5000 Namur. 
Service de Pneumologie, CHU-UCL-Namur, Site de Godinne Avenue du Docteur 
Therasse,1, 5530 Yvoir. 







PROFESSEUR ERIC MARCHAND 
      
       
 
Nom et prénom du patient :  
 
___________________________________ 




1.  Données personnelles : 
 
✓ Date de naissance :          /            /            
✓ Age : _______________ 
✓ Sexe :           Homme   -    Femme  
✓ Tabagisme :    Oui     -    Jamais    -    Ancien(ne) fumeur-se 
 
Nombre de cigarettes par jour : ____________________  
 
Nombre de paquet par année : _____________________ 
 
 
2. Données anthropomorphiques : 
 
✓ Poids : ____________________ 
✓ Taille : ____________________ 
 
 
3. Données médicales : 
 
a) Pour patients sains :  
Souffrez-vous d’une maladie respiratoire chronique ? 
La ou lesquelles ; depuis quand 
 
 
Souffrez-vous d’une maladie cardiaque? 
La ou lesquelles ; depuis quand 
 
 
b) Pour patients BPCO : 
Depuis quand êtes vous soigné pour votre bronchopneumopathie 
chronique obstructive (bronchite chronique-emphysème) ; depuis 

















- Avez-vous présenté une dégradation de votre état respiratoire  
ayant nécessité la prise d’antibiotiques ou de corticostéroïdes 
(Medrol) au cours des 12 derniers mois ? Quand (date), combien 




                           ______________________________________________________ 
 
 
                                     







         _____________________________________________________ 
         _____________________________________________________ 
         _____________________________________________________ 





































6. Traitement : 
 
a) Quels médicaments prenez-vous actuellement ? 





















b)   A quelle heure avez-vous pris vos inhalés médicaments la dernière fois ? 
 
1 Médicament :    Date et heure 
2 Médicament :    Date et heure 
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CENTRE MÉDICAL DE L’UNIVERSITÉ DE CALIFORNIE (UCSD), SAN DIEGO 
PROGRAMME DE RÉADAPTATION RESPIRATOIRE 
QUESTIONNAIRE SUR L’ESSOUFFLEMENT 
© 1995 The Regents of the University of California 
 
Veuillez indiquer à quel point vous êtes essoufflé(e) lorsque vous faites, ou si 
vous deviez faire, chacune des activités suivantes. Ne passez aucune question. 
Si vous n’avez jamais fait ou ne faites plus ce type d’activité, essayez d’évaluer 
au mieux à quel point vous seriez essoufflé(e) si vous deviez la faire. Veuillez 





Lorsque je fais les activités suivantes (ou si je devais les faire), je 








 4 Très important 
 5 Maximal (ou bien je ne suis pas capable de 










1. Me brosser les dents .......................................... 0 1 2  4 5 
 
 
Paul s’est senti moyennement essoufflé au cours des 7 derniers jours quand il se brossait les dents.  
Il a donc entouré le chiffre 3. 
 
 
2. Tondre la pelouse ............................................... 0 1 2 3 4  
 
 
Anne n’a jamais tondu la pelouse mais pense qu’elle aurait été trop essoufflée pour le faire au 
cours  
des 7 derniers jours. Elle a donc entouré le chiffre 5. 
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Lorsque je fais les activités suivantes (ou si je devais les faire), je 








 4 Très important 
 5 Maximal (ou bien je ne suis pas capable de 






repos ........................................................................................ 0 1 2 3
 .............................................................................. 4 5 
2. Marcher sur un terrain plat à mon propre 
rythme ..................................................................................... 0 1 2 3
 .............................................................................. 4 5 
3. Marcher sur un terrain plat avec d’autres 
personnes  
de mon âge 
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 ................................................................................................ 0 1 2 3
 .............................................................................. 4 5 
4. Monter une 
côte .......................................................................................... 0 1 2 3
 .............................................................................. 4 5 
5. Monter des 
marches ................................................................................... 0 1 2 3
 .............................................................................. 4 5 
6. Manger .................................................................................... 0 1 2 3
 .............................................................................. 4 5 
7. Me lever d’une 
chaise ...................................................................................... 0 1 2 3
 .............................................................................. 4 5 
8. Me brosser les 
dents ........................................................................................ 0 1 2 3
 .............................................................................. 4 5 
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9. Me raser et/ou me 
coiffer ...................................................................................... 0 1 2 3
 .............................................................................. 4 5 
10. Prendre une douche/un 
bain .......................................................................................... 0 1 2 3
 .............................................................................. 4 5 
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Lorsque je fais les activités suivantes (ou si je devais les faire), je 








 4 Très important 
 5 Maximal (ou bien je ne suis pas capable de 





11. M’habiller ........................................................................................ 0 1 2 3
 .............................................................................. 4 5 
12. Ramasser des objets et les 
ranger .............................................................................................. 0 1 2 3
 .............................................................................. 4 5 
13. Faire la 
vaisselle ........................................................................................... 0 1 2 3
 .............................................................................. 4 5 




l’aspirateur ...................................................................................... 0 1 2 3
 .............................................................................. 4 5 
15. Faire le 
lit ..................................................................................................... 0 1 2 3
 .............................................................................. 4 5 
16. Faire les 
courses ............................................................................................ 0 1 2 3
 .............................................................................. 4 5 
17. Faire la lessive à la 
main................................................................................................. 0 1 2 3
 .............................................................................. 4 5 
18. Laver la 
voiture ............................................................................................. 0 1 2 3
 .............................................................................. 4 5 
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19. Tondre la 
pelouse ............................................................................................ 0 1 2 3
 .............................................................................. 4 5 
20. Arroser la 
pelouse ............................................................................................ 0 1 2 3
 .............................................................................. 4 5 
21. Activités 
sexuelles .......................................................................................... 0 1 2 3
 .............................................................................. 4 5 
  








 4 Très important 
 5 Maximal (ou bien je ne suis pas capable de 






À quel point suis-je limité(e) dans ma vie quotidienne par : 
 
22. Le fait d’être 
essoufflé(e) ...................................................................................... 0 1 2 3
 .............................................................................. 4 5 
23. La peur de me faire mal en faisant trop 
d’efforts ........................................................................................... 0 1 2 3
 .............................................................................. 4 5 
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24. La peur d’être 
essoufflé(e) ...................................................................................... 0 1 2 3
 .............................................................................. 4 5 
 
 
 
